HOME >> BIOLOGY >> NEWS
Interdisciplinary team develops guidelines for treating severely injured patients

If someone is injured in an automobile collision or is severely burned, emergency room physicians across the country would probably take similar steps to stabilize each condition. But subsequent treatment in the intensive care unit or operating room is less well established and may vary significantly.

That is likely to change based on the work of an interdisciplinary team of dozens of scientists and physicians funded by the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). Drawing from the best available evidence, the team is developing a series of standard procedures for the care of severely injured patients. The guidelines will describe how to implement the most successful treatment protocols in the clinic and will include summaries of each procedure ready to print on 3-by-5 index cards for quick bedside reference.

The team's first article--on mechanical ventilation--appeared in the September 2005 issue of the Journal of Trauma: Injury, Infection, and Critical Care. Planned future topics will cover resuscitation, prevention and treatment of venous blood clots, diagnosis of ventilator-associated pneumonia, blood sugar control, nutritional support, transfusion thresholds, and sedation. The team chose to cover aspects of care for which practices vary the most and those that have the greatest potential to influence patient outcomes.

The scientific team is part of a collaborative, NIGMS-supported initiative called the Inflammation and Host Response to Injury "glue grant" program. Glue grants bring together scientists with diverse expertise to address major biomedical questions that are beyond the scope of any one research group--in this case, to uncover why patients who experience comparable traumatic injuries can have dramatically different outcomes. This project was launched in 2001 with a 5-year award totaling $37 million.

"This program shows how partnerships between clinical and
'"/>

Contact: Kirstie Saltsman
saltsmank@nigms.nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
19-Apr-2006


Page: 1 2 3

Related biology news :

1. Interdisciplinary grant to Yale: Creating nanodevices for delivery of vaccines
2. N.C. A&T food scientist develops process for allergen-free peanuts
3. MIT develops nanoparticles to battle cancer
4. UC develops new approach to Web-based drug withdrawal warnings
5. Engineer ramps up protein production, develops versatile viral spheres
6. Hopkins develops online tool to aid research on certain orphan diseases
7. U of I scientist develops enzyme inhibitor that may slow cancer growth
8. West develops taste for primates
9. OHSU researcher develops first animal model to treat devasting head and neck cancers
10. Novel stem cell technology develops a new cell for repairing spinal cord injuries
11. Georgia Tech develops technology for more compact, inexpensive spectrometers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: